Kodu・Aktsiate loetelu・Iovance Biotherapeutics Inc

Iovance Biotherapeutics Inc

Suletud

SektorTervishoid

4.37 1.63

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.29

Max

4.47

Põhinäitajad
By Trading Economics
Sissetulek	-7.1M -79M
Müük	-15M 71M
Aktsiakasum	-0.19
Kasumimarginaal	-110.661
Töötajad	975
EBITDA	-3.4M -71M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+126.85% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	208M 1.9B
Eelmine avamishind	2.74
Eelmine sulgemishind	4.37

Uudiste sentiment

By Acuity

34%

66%

130 / 340 Pingereas Healthcare

Iovance Biotherapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. aug 2026, 19:51 UTC

Iovance Biotherapeutics is rising amid broader market strength from falling crude oil prices and positive economic data, despite lingering inflation concerns.

3. aug 2026, 19:51 UTC

Iovance Biotherapeutics shares are higher today, rebounding from an earlier low. The stock has advanced since Friday, amid positive market sentiment.

31. juuli 2026, 23:41 UTC

Iovance Biotherapeutics shares are higher in after-market trading, maintaining gains since Friday's close amid broader market volatility following a decline in Apple shares.

30. juuli 2026, 23:51 UTC

Iovance Biotherapeutics shares are lower in after-market trading, reflecting ongoing weakness and pulling back from a brief session high earlier.

29. juuli 2026, 15:16 UTC

Iovance Biotherapeutics Inc shares are lower today, continuing a trend of declines over the past six sessions with no specific news identified.

28. juuli 2026, 23:56 UTC

Iovance Biotherapeutics shares declined in after-market trading, continuing a trend of lower finishes over the past five sessions. No specific news was identified.

27. juuli 2026, 19:36 UTC

Social Media

Iovance Biotherapeutics is lower today, continuing a trend of declines over four consecutive trading days. Earlier, shares rebounded from a session low.

24. juuli 2026, 19:12 UTC

Iovance Biotherapeutics Inc shares are lower today, continuing a downward trend amid broader market volatility influenced by falling oil prices and geopolitical tensions.

22. juuli 2026, 23:11 UTC

Iovance Biotherapeutics shares are higher in after-market trading, supported by gains in the Biotechnology sub-sector. The stock remains near its one-month trading range high.

21. juuli 2026, 19:46 UTC

Social Media

Iovance Biotherapeutics shares are higher amid positive social media sentiment and favorable earnings reports from peers, including General Motors and Novartis.

20. juuli 2026, 19:16 UTC

Social Media

Iovance Biotherapeutics Inc shares are higher today, with significant trading volume reaching 23.48 million. The stock has fluctuated between 4.44 and 5.07 during the session.

Võrdlus sarnastega

Hinnamuutus

Iovance Biotherapeutics Inc Prognoos

Hinnasiht

By TipRanks

126.85% tõus

12 kuu keskmine prognoos

Keskmine 9.8 USD 126.85%

Kõrge 14 USD

Madal 5 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Iovance Biotherapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Iovance Biotherapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

130 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.